<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20346">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02842021</url>
  </required_header>
  <id_info>
    <org_study_id>SGT-26-01</org_study_id>
    <nct_id>NCT02842021</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis</brief_title>
  <official_title>A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sol-Gel Technologies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sol-Gel Technologies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads
      and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory
      interdigital tinea pedis in subjects 12 years of age and older. The results of this study
      will be utilized to perform power calculations for the Phase 3 pivotal trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete cure at Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>The primary efficacy comparison between S2G6T-1 vs. rest of study arms will be based on the percentage of subjects at day 29 with complete cure of interdigital tinea pedis.mycological cure (i.e. negative dermatophyte culture and negative KOH) and clinical cure (i.e. absence of erythema, scaling and pruritus {scores of 0, each})</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in Tinea pedis SymptomS through treatment period.</measure>
    <time_frame>Day 8</time_frame>
    <description>comparison of Patient Assessment between S2G6T-1 vs. rest of study arms will be based on the percentage of subjects at day 8 with achieving decrease from baseline in the total score for pruritus and burning.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>S2G6T-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S2G6T-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S2G6T-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S2G6T-4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical Cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S2G6T-1</intervention_name>
    <description>Twice a day topical cream</description>
    <arm_group_label>S2G6T-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S2G6T-2</intervention_name>
    <description>Twice a day topical cream</description>
    <arm_group_label>S2G6T-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S2G6T-3</intervention_name>
    <description>Twice a day topical cream</description>
    <arm_group_label>S2G6T-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S2G6T-4</intervention_name>
    <description>Twice a day topical cream</description>
    <arm_group_label>S2G6T-4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability and willingness to sign a written informed consent and /or assent (age
             appropriate).

          2. Male or Female subjects 12 years of age or older.

          3. A clinical diagnosis of interdigital tinea pedis on one or both feet characterized by
             clinical evidence of a tinea infection.

          4. A sum of at least five (5) for signs (erythema and scaling) by the investigator on
             the selected target foot, and a score of at least five (5) for each symptom: pruritus
             (itching) and burning: and a sum of at least twelve (12) for both symptoms (pruritus
             and burning) by the subject on the PATSS.

          5. Mycological evidence of the presence of fungi confirmed by the detection of fungal
             hyphae on a microscopic KOH wet mount.

          6. Females of child-bearing potential must have a negative urine pregnancy test and must
             agree to use an effective form of contraception during the study .

          7. Must be in good general health as determined by medical history and free of any
             disease that in the investigator's opinion might interfere with the study
             evaluations.

          8. Must be able to communicate, be able to understand the study procedures, and be
             willing to comply with the study requirements.

        Exclusion Criteria:

          1. The presence of confluent diffuse moccasin-type tinea pedis.

          2. Negative KOH microscopy test to assess presence of hyphae.

          3. Onychomycosis of the toenails, involving â‰¥ 20% of the area of either great toenail or
             involvement of more than five toenails in total.

          4. Concurrent tinea infection or bacterial skin infection on the feet.

          5. Female subjects who are pregnant and/or nursing or planning a pregnancy during the
             course of the trial.

          6. Recent history of or currently known to abuse drugs or alcohol.

          7. History of intolerance or hypersensitivity to Econazole Nitrate, Mometasone Furoate,
             or other imidazole agents.

          8. Presence of any other infection of the foot or other disease process that might
             confound the treatment evaluation.

          9. Having a life-threatening condition or immunocompromised (e.g., autoimmune deficiency
             syndrome, cancer, unstable angina, or myocardial infarction) within the last 6
             months.

         10. Unable to communicate or cooperate with the investigator due to language barriers,
             poor mental development, or impaired cerebral function.

         11. Current participation in a clinical drug research study or recent participation in a
             clinical trial within 30 days of Baseline.

         12. Using the following medications prior to Baseline:

               1. Antipruritics, including antihistamines within 3 days (72 hours).

               2. Topical corticosteroids, antibiotics or antifungal therapies within 4 weeks.

               3. Systemic corticosteroids, antibiotics or antifungal therapies within 12 weeks.

               4. Oral terbinafine or itraconazole within 12 weeks.

               5. Immunosuppressive medication or radiation therapy within 12 weeks.

               6. Any other topical medicated topical treatments to the treatment area(s) within 7
                  days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen O Ashenfelter, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Cu-Tech, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ofra Levy-Hacham, Ph.D</last_name>
    <phone>+972733729453</phone>
    <phone_ext>9453</phone_ext>
    <email>Ofra.Levy-Hacham@sol-gel.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ofer Toledano, Ph.D</last_name>
    <phone>+972733729452</phone>
    <phone_ext>9452</phone_ext>
    <email>Ofer.Toledano@sol-gel.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>TCR Medical Corporation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra K Adsit, MD</last_name>
      <phone>858-571-6800</phone>
      <email>sadsit@therapeuticsresearch.com</email>
    </contact>
    <investigator>
      <last_name>Neal D Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Vega</last_name>
      <phone>858-278-8470</phone>
      <email>carlos@univct.com</email>
    </contact>
    <contact_backup>
      <last_name>Ryan Riendeau</last_name>
      <phone>858-278-8470</phone>
      <email>ryan@univct.com</email>
    </contact_backup>
    <investigator>
      <last_name>Walter Nahm, PhD., MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Stopnystky</last_name>
      <phone>727-724-3316</phone>
      <email>kim@tbmr.net</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Wolford</last_name>
      <phone>727-724-3316</phone>
      <email>wolford@tbmr.net</email>
    </contact_backup>
    <investigator>
      <last_name>Srikanth Malempati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tory Sullivan, MD, PA</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John DeFelice</last_name>
      <email>john@sullivandermatology.com</email>
    </contact>
    <investigator>
      <last_name>Tory Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Douglas</last_name>
      <phone>904-458-0411</phone>
      <email>ydouglas@parkavedermatology.com</email>
    </contact>
    <investigator>
      <last_name>George Schmieder, Do</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Research for Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Willis</last_name>
      <phone>443-686-0012</phone>
      <email>wwilliscrc@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Max Weisfeld, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alissa R Prochniak</last_name>
      <phone>763-571-4200</phone>
      <email>aprochniak@associatedskincare.com</email>
    </contact>
    <investigator>
      <last_name>Steven Kempers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlenny Carbajal</last_name>
      <phone>505-247-4220</phone>
      <email>mcarbajal@abqdermtrials.com</email>
    </contact>
    <investigator>
      <last_name>Alicia D Bucko, DO, JD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Search of Rochester, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>146232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Voelkl</last_name>
      <phone>585-697-1818</phone>
      <email>jvoelkl@dermrochester.com</email>
    </contact>
    <investigator>
      <last_name>John H. Tu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Priest</last_name>
      <phone>615-383-9660</phone>
      <email>apriest@tnclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Michael H Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael T Jarratt, MD</last_name>
      <phone>512-349-9889</phone>
      <email>mjarratt@dermresearch.net</email>
    </contact>
    <investigator>
      <last_name>Janet C DuBois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terry M Jones, MD</last_name>
      <phone>979-774-5933</phone>
      <phone_ext>933</phone_ext>
      <email>info@js-studies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce &amp; Associates, PA / The Center for Skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Garcia</last_name>
      <phone>713-985-0210</phone>
      <phone_ext>178</phone_ext>
      <email>igarcia@sba-skincare.com</email>
    </contact>
    <investigator>
      <last_name>Tracy Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce &amp; Associates ,PA / The Center for Skin Research</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Garcia</last_name>
      <phone>713-985-0210</phone>
      <phone_ext>178</phone_ext>
      <email>igarcia@sba-skincare.com</email>
    </contact>
    <investigator>
      <last_name>Suzanne Bruce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DermResearch New Braunfels</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebeccca Bennett</last_name>
      <phone>830-387-5768</phone>
      <email>rgonzales@dermresearch.net</email>
    </contact>
    <investigator>
      <last_name>Vicente Quintero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Gonzales</last_name>
      <phone>210-949-0807</phone>
      <email>mgonzales@endeavorct.com</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Rodriguez</last_name>
      <phone>210-949-0807</phone>
      <email>lisa@endeavorct.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Pollak, DPM, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Pyne</last_name>
      <phone>801-269-0135</phone>
      <email>christine@dermatologyresearch.net</email>
    </contact>
    <investigator>
      <last_name>Leonard J. Swinyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Education &amp; Research Foundation Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Furguson</last_name>
      <phone>434-847-8400</phone>
      <email>aferguson@educationandresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Sue Foster</last_name>
      <phone>434-847-8400</phone>
      <email>sfoster@educationandresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>David C. Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Mullen</last_name>
      <phone>757-625-0151</phone>
      <email>bmullen@vcrinc.org</email>
    </contact>
    <investigator>
      <last_name>David M. Pariser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 17, 2017</lastchanged_date>
  <firstreceived_date>July 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
